Fasenra eliminated oral corticosteroid use in a majority of OCS-dependent patients with asthma in PONENTE Phase IIIb trial
62% of patients stopped OCS use in largest ever steroid sparing trial in severe asthmaHigh-level results from the PONENTE Phase IIIb open-label trial showed Fasenra (benralizumab) eliminated the use of maintenance oral corticosteroids (OCS) in OCS-dependent asthma patients with a broad range of blood eosinophil counts. Severe asthma is an often debilitating condition affecting approximately 34 million people worldwide.[1,2] More than one-third of these patients currently use chronic or intermittent OCS on top of other therapies to control their symptoms and exacerbations.[3,4] However,